Check out
our Latest News

Stockton Road Capital partners with GF Capital Private Equity Fund to acquire Airborne

Stockton Road Capital has advised and partnered with the GF Capital Private Equity Fund LP in its acquisition of Airborne®, a leading line of dietary supplements that support immune health. The management team of Airborne, which is led by Marti Morfitt, also participated meaningfully in the investment.

Airborne is a dietary supplement that was created by a school teacher to help support her immune system. The supplement is a proprietary blend of 17 vitamins, minerals and herbs. The key ingredients in Airborne help support a healthy immune system as shown in scientific studies and medical journals. Airborne products can be found in food, drug and mass retailers across the United States and Canada. For more information on Airborne, visit

“Airborne is an outstanding product that has strong consumer awareness and very significant retailer support and distribution. As a result, Airborne is one of the best selling product lines in the overall cough/cold category. I look forward to working with and supporting my partners at GF Capital and with the outstanding management team of Airborne to build upon this iconic consumer brand’s already significant level of success,” said Joe Rhodes, Managing Partner of Stockton Road Capital.

Ms. Morfitt most recently served as chief executive officer and a director of CNS, Inc., a publicly traded marketer of consumer health care products. During her nine-year tenure, Ms. Morfitt and her team successfully completed a performance turnaround at CNS, returning the company to profitability and transforming it into a growing consumer health products company with flagship brands that include Breathe Right® nasal strips and FiberChoice® daily fiber supplement brands. CNS was sold to GlaxoSmithKline in December 2006.

Airborne was represented by Sawaya Segalas & Co., a leading investment banking firm to the consumer products industry.


Joe Rhodes
Managing Partner

424-372-3179 (w)
917-301-1308 (c)
Los Angeles, CA